# Novoron Bioscience

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/novoron-bioscience

- Industry: Biotechnology
- Headquarters: San Diego, US
- Website: www.novoron.com
- Total disclosed funding: $3M
- Latest round: Seed (Nov 16, 2021)
- Investors on record: 2

## About

Based in San Diego, CA, Novoron Bioscience Inc. specializes in the development of innovative therapies targeting neurodegenerative diseases and enhancing neurological health through advanced drug solutions.Novoron Bioscience Inc. focuses on developing novel therapies for neurodegenerative conditions. The company was founded by A Bright and Shawn Gahr. It recently raised USD 3.000 mn in Seed funding on November 16, 2021, led by Two Bear Capital. The total amount raised by the company is USD 3.000 mn, with 8 deals reported.Novoron Bioscience specializes in the development of innovative therapies aimed at addressing neurodegenerative diseases and enhancing neurological health. The company's core product offerings include small molecule therapies designed to inhibit the spread of prion-like proteins, which contribute to neurodegeneration and cognitive decline. Additionally, Novoron focuses on enhancing the regenerative capacity of the spinal cord following traumatic injuries, creating solutions that promote recovery and restore functionality. Their research and drug development efforts are directed toward both preclinical and clinical applications, with an emphasis on multi-modality discovery and optimized drug delivery. Novoron’s products are targeted toward healthcare providers, research institutions, and pharmaceutical partners across North America and Europe.Novoron Bioscience's revenue structure is primarily based on partnerships and collaborations within the pharmaceutical and healthcare sectors. The company engages with research institutions and healthcare providers for the distribution and application of its therapeutic offerings, leveraging strategic alliances to penetrate the market effectively. Revenue generation is facilitated through licensing agreements, development partnerships, and milestone payments associated with the advancement of their drug candidates through various stages of clinical trials. The specifics of pricing and transaction structures are tailored to the unique characteristics of their therapies and the agreements established with their partners, ensuring alignment with regulatory standards and market needs. Novoron’s focus on innovative solutions positions them competitively within the biopharmaceutical landscape, influencing their revenue prospects as their product offerings advance toward commercialization.In November 2021, Novoron Bioscience Inc. raised USD 3.000 mn in Seed funding, led by Two Bear Capital. The funding will be utilized to develop Novoron's leading drug candidate, NOVO-118, which is expected to play a significant role in their therapeutic portfolio. The company plans to explore expansion into additional markets within North America and Europe, enhancing their presence in regions where neurodegenerative diseases are prevalent. As Novoron continues to innovate and advance their drug pipeline, they aim to solidify partnerships and collaborations that further support their growth objectives.

## Funding rounds

- Seed, Nov 16, 2021, $3M — Two Bear Capital
- Seed, Mar 3, 2018 — Backstage Capital

## Investors

- Backstage Capital (https://capitalatlas.ai/funds/backstage-capital) — Seed
- Two Bear Capital (https://capitalatlas.ai/funds/two-bear-capital) — Seed